Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 85 to 93 of 93 entries
Sorted by: Best Match Show Resources per page
[The assessment of the price of a medicine: not only on the basis of the value for the patient].

Nederlands tijdschrift voor geneeskunde

Hollak CEM, van den Berg S, Timmers L, Canoy M.
PMID: 34523839
Ned Tijdschr Geneeskd. 2021 Sep 09;165.

Before admission to the insured package, the price of a medicine is usually assessed on the basis of the value of the medicine for the patient: a large effect size on health and survival may cost more than a...

Cite
Hollak CEM, van den Berg S, Timmers L, et al. Beoordeling van de prijs van een geneesmiddel. [The assessment of the price of a medicine: not only on the basis of the value for the patient]. Ned Tijdschr Geneeskd. 2021;165
Hollak, C. E. M., van den Berg, S., Timmers, L., & Canoy, M. (2021). Beoordeling van de prijs van een geneesmiddel. [The assessment of the price of a medicine: not only on the basis of the value for the patient]. Nederlands tijdschrift voor geneeskunde, 165.
Hollak, Carla E M, et al. "Beoordeling van de prijs van een geneesmiddel." [The assessment of the price of a medicine: not only on the basis of the value for the patient]. Nederlands tijdschrift voor geneeskunde vol. 165 (2021).
Hollak CEM, van den Berg S, Timmers L, Canoy M. Beoordeling van de prijs van een geneesmiddel. [The assessment of the price of a medicine: not only on the basis of the value for the patient]. Ned Tijdschr Geneeskd. 2021 Sep 09;165. Dutch. PMID: 34523839.
Copy Download .nbib Format: NLM
Consequences of the 340B Drug Pricing Program.

The New England journal of medicine

Desai S, McWilliams JM.
PMID: 29791824
N Engl J Med. 2018 May 24;378(21):2053-2054. doi: 10.1056/NEJMc1802999.

No abstract available.

Cite
Desai S, McWilliams JM. Consequences of the 340B Drug Pricing Program. N Engl J Med. 2018;378(21):2053-2054doi: 10.1056/NEJMc1802999.
Desai, S., & McWilliams, J. M. (2018). Consequences of the 340B Drug Pricing Program. The New England journal of medicine, 378(21), 2053-2054. https://doi.org/10.1056/NEJMc1802999
Desai, Sunita, and McWilliams, J Michael. "Consequences of the 340B Drug Pricing Program." The New England journal of medicine vol. 378,21 (2018): 2053-2054. doi: https://doi.org/10.1056/NEJMc1802999
Desai S, McWilliams JM. Consequences of the 340B Drug Pricing Program. N Engl J Med. 2018 May 24;378(21):2053-2054. doi: 10.1056/NEJMc1802999. PMID: 29791824; PMCID: PMC8320346.
Copy Download .nbib Format: NLM
Comment on: 'Value-Based Pricing Alternatives for Personalised Drugs: Implications of Asymmetric Information and Competition'.

Applied health economics and health policy

Garattini L, Freemantle N.
PMID: 32016830
Appl Health Econ Health Policy. 2020 Jun;18(3):453-454. doi: 10.1007/s40258-020-00552-1.

No abstract available.

Cite
Garattini L, Freemantle N. Comment on: 'Value-Based Pricing Alternatives for Personalised Drugs: Implications of Asymmetric Information and Competition'. Appl Health Econ Health Policy. 2020;18(3):453-454doi: 10.1007/s40258-020-00552-1.
Garattini, L., & Freemantle, N. (2020). Comment on: 'Value-Based Pricing Alternatives for Personalised Drugs: Implications of Asymmetric Information and Competition'. Applied health economics and health policy, 18(3), 453-454. https://doi.org/10.1007/s40258-020-00552-1
Garattini, Livio, and Freemantle, Nick. "Comment on: 'Value-Based Pricing Alternatives for Personalised Drugs: Implications of Asymmetric Information and Competition'." Applied health economics and health policy vol. 18,3 (2020): 453-454. doi: https://doi.org/10.1007/s40258-020-00552-1
Garattini L, Freemantle N. Comment on: 'Value-Based Pricing Alternatives for Personalised Drugs: Implications of Asymmetric Information and Competition'. Appl Health Econ Health Policy. 2020 Jun;18(3):453-454. doi: 10.1007/s40258-020-00552-1. PMID: 32016830.
Copy Download .nbib Format: NLM
Availability of Cost-effectiveness Studies for Drugs With High Medicare Part D Expenditures.

JAMA network open

Tisdale RL, Ma I, Vail D, Bhattacharya J, Goldhaber-Fiebert JD, Heidenreich PA, Sandhu AT.
PMID: 34143189
JAMA Netw Open. 2021 Jun 01;4(6):e2113969. doi: 10.1001/jamanetworkopen.2021.13969.

IMPORTANCE: Prescription drug spending in the US requires policy intervention to control costs and improve the value obtained from pharmaceutical spending. One such intervention is to apply cost-effectiveness evidence to decisions regarding drug coverage and pricing, but this intervention...

Cite
Tisdale RL, Ma I, Vail D, et al. Availability of Cost-effectiveness Studies for Drugs With High Medicare Part D Expenditures. JAMA Netw Open. 2021;4(6):e2113969doi: 10.1001/jamanetworkopen.2021.13969.
Tisdale, R. L., Ma, I., Vail, D., Bhattacharya, J., Goldhaber-Fiebert, J. D., Heidenreich, P. A., & Sandhu, A. T. (2021). Availability of Cost-effectiveness Studies for Drugs With High Medicare Part D Expenditures. JAMA network open, 4(6), e2113969. https://doi.org/10.1001/jamanetworkopen.2021.13969
Tisdale, Rebecca L, et al. "Availability of Cost-effectiveness Studies for Drugs With High Medicare Part D Expenditures." JAMA network open vol. 4,6 (2021): e2113969. doi: https://doi.org/10.1001/jamanetworkopen.2021.13969
Tisdale RL, Ma I, Vail D, Bhattacharya J, Goldhaber-Fiebert JD, Heidenreich PA, Sandhu AT. Availability of Cost-effectiveness Studies for Drugs With High Medicare Part D Expenditures. JAMA Netw Open. 2021 Jun 01;4(6):e2113969. doi: 10.1001/jamanetworkopen.2021.13969. PMID: 34143189; PMCID: PMC8214163.
Copy Download .nbib Format: NLM
NHS spent 8% more on medicines last year.

BMJ (Clinical research ed.)

Torjesen I.
PMID: 27881369
BMJ. 2016 Nov 22;355:i6320. doi: 10.1136/bmj.i6320.

No abstract available.

Cite
Torjesen I. NHS spent 8% more on medicines last year. BMJ. 2016;355:i6320doi: 10.1136/bmj.i6320.
Torjesen, I. (2016). NHS spent 8% more on medicines last year. BMJ (Clinical research ed.), 355i6320. https://doi.org/10.1136/bmj.i6320
Torjesen, Ingrid. "NHS spent 8% more on medicines last year." BMJ (Clinical research ed.) vol. 355 (2016): i6320. doi: https://doi.org/10.1136/bmj.i6320
Torjesen I. NHS spent 8% more on medicines last year. BMJ. 2016 Nov 22;355:i6320. doi: 10.1136/bmj.i6320. PMID: 27881369.
Copy Download .nbib Format: NLM
The Impact of Shortages on Medication Prices: Implications for Shortage Prevention.

Drugs

Alevizakos M, Detsis M, Grigoras CA, Machan JT, Mylonakis E.
PMID: 27770351
Drugs. 2016 Oct;76(16):1551-1558. doi: 10.1007/s40265-016-0651-7.

BACKGROUND: Medication shortages are frequent and have clinical and financial ramifications; however, their effect on drug prices remains unknown.OBJECTIVE: To examine price progression of medications affected by a shortage.METHODS: We collected prices of medications covered under Medicare Part B,...

Cite
Alevizakos M, Detsis M, Grigoras CA, et al. The Impact of Shortages on Medication Prices: Implications for Shortage Prevention. Drugs. 2016;76(16):1551-1558doi: 10.1007/s40265-016-0651-7.
Alevizakos, M., Detsis, M., Grigoras, C. A., Machan, J. T., & Mylonakis, E. (2016). The Impact of Shortages on Medication Prices: Implications for Shortage Prevention. Drugs, 76(16), 1551-1558. https://doi.org/10.1007/s40265-016-0651-7
Alevizakos, Michail, et al. "The Impact of Shortages on Medication Prices: Implications for Shortage Prevention." Drugs vol. 76,16 (2016): 1551-1558. doi: https://doi.org/10.1007/s40265-016-0651-7
Alevizakos M, Detsis M, Grigoras CA, Machan JT, Mylonakis E. The Impact of Shortages on Medication Prices: Implications for Shortage Prevention. Drugs. 2016 Oct;76(16):1551-1558. doi: 10.1007/s40265-016-0651-7. PMID: 27770351.
Copy Download .nbib Format: NLM
Seven therapeutic categories account for most drug cost increases.

Managed care (Langhorne, Pa.)

[No authors listed]
PMID: 22259880
Manag Care. 2011 Dec;20(12):69.

No abstract available.

Cite
Seven therapeutic categories account for most drug cost increases. Manag Care. 2011;20(12):69
(2011). Seven therapeutic categories account for most drug cost increases. Managed care (Langhorne, Pa.), 20(12), 69.
"Seven therapeutic categories account for most drug cost increases." Managed care (Langhorne, Pa.) vol. 20,12 (2011): 69.
Seven therapeutic categories account for most drug cost increases. Manag Care. 2011 Dec;20(12):69. PMID: 22259880.
Copy Download .nbib Format: NLM
Impact of zero-mark-up medicines policy on hospital revenue structure: a panel data analysis of 136 public tertiary hospitals in China, 2012-2020.

BMJ global health

Cheng H, Zhang Y, Sun J, Liu Y.
PMID: 34725041
BMJ Glob Health. 2021 Nov;6(11). doi: 10.1136/bmjgh-2021-007089.

OBJECTIVE: To quantify the overall and dynamic effects of the implementation of the zero-mark-up medicines policy on the proportionate revenue generated from medicines, medical services and government subsidies at Chinese tertiary public hospitals.METHODS: The revenue data of 136 tertiary...

Cite
Cheng H, Zhang Y, Sun J, et al. Impact of zero-mark-up medicines policy on hospital revenue structure: a panel data analysis of 136 public tertiary hospitals in China, 2012-2020. BMJ Glob Health. 2021;6(11)doi: 10.1136/bmjgh-2021-007089.
Cheng, H., Zhang, Y., Sun, J., & Liu, Y. (2021). Impact of zero-mark-up medicines policy on hospital revenue structure: a panel data analysis of 136 public tertiary hospitals in China, 2012-2020. BMJ global health, 6(11), . https://doi.org/10.1136/bmjgh-2021-007089
Cheng, Hanchao, et al. "Impact of zero-mark-up medicines policy on hospital revenue structure: a panel data analysis of 136 public tertiary hospitals in China, 2012-2020." BMJ global health vol. 6,11 (2021). doi: https://doi.org/10.1136/bmjgh-2021-007089
Cheng H, Zhang Y, Sun J, Liu Y. Impact of zero-mark-up medicines policy on hospital revenue structure: a panel data analysis of 136 public tertiary hospitals in China, 2012-2020. BMJ Glob Health. 2021 Nov;6(11). doi: 10.1136/bmjgh-2021-007089. PMID: 34725041; PMCID: PMC8562510.
Copy Download .nbib Format: NLM
Drug bill cuts force firms overseas.

Nature biotechnology

Saegusa A.
PMID: 9624670
Nat Biotechnol. 1998 Jun;16(6):506-7. doi: 10.1038/nbt0698-506b.

No abstract available.

Cite
Saegusa A. Drug bill cuts force firms overseas. Nat Biotechnol. 1998;16(6):506-7doi: 10.1038/nbt0698-506b.
Saegusa, A. (1998). Drug bill cuts force firms overseas. Nature biotechnology, 16(6), 506-7. https://doi.org/10.1038/nbt0698-506b
Saegusa, A. "Drug bill cuts force firms overseas." Nature biotechnology vol. 16,6 (1998): 506-7. doi: https://doi.org/10.1038/nbt0698-506b
Saegusa A. Drug bill cuts force firms overseas. Nat Biotechnol. 1998 Jun;16(6):506-7. doi: 10.1038/nbt0698-506b. PMID: 9624670.
Copy Download .nbib Format: NLM
Showing 85 to 93 of 93 entries